Entering text into the input field will update the search result below

Seattle Genetics' (SGEN) CEO Clay Siegall on Q1 2020 Results - Earnings Call Transcript

May 01, 2020 12:01 AM ETSeagen Inc. (SGEN)
SA Transcripts profile picture
SA Transcripts

Seattle Genetics, Inc. (NASDAQ:SGEN) Q1 2020 Earnings Conference Call April 30, 2020 4:30 PM ET

Company Participants

Peggy Pinkston – Vice President, Investor Relations

Clay Siegall – President and Chief Executive Officer

Chip Romp – Executive Vice President-Commercial

Todd Simpson – Chief Financial Officer

Roger Dansey – Chief Medical Officer

Conference Call Participants

Salveen Richter – Goldman Sachs

Kennen MacKay – RBC Capital Markets

Michael Schmidt – Guggenheim

Greg Harrison – Bank of America

Chad Messer – Needham & Company

Gena Wang – Barclays

Joe Catanzaro – Piper Jaffray

Andrew Berens – SVB

Stephen Willey – Stifel

George Farmer – BMO Capital Market

Andy Hsieh – William Blair

Silvan Tuerkcan – Oppenheimer


Good day and welcome to the Seattle Genetics First Quarter 2020 Financial Results Conference Call. Today’s call is being recorded.

At this time I would like to turn the conference over to Ms. Peggy Pinkston, Vice President of Investor Relations. Please go ahead.

Peggy Pinkston

Thank you, operator, and good afternoon, everyone. I’d like to welcome all of you to Seattle Genetics first quarter 2020 conference call. With me today are Clay Siegall, President and Chief Executive Officer; Chip Romp, Executive Vice President-Commercial, Todd Simpson, Chief Financial Officer; and Roger Dansey, Chief Medical Officer.

Accompanying today’s conference call are supporting slides, which are available on our website in the Investors section, Events and Presentations page. Following our prepared remarks, we’ll open the line for questions. [Operator Instructions]

Today’s conference call will include forward-looking statements regarding future or anticipated events and results, including the company’s 2020 financial outlook, anticipated product sales, revenues, costs and expenses, and timing to achieve potential clinical and regulatory milestones, including data readouts, regulatory submissions and approvals.

Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.